New Zealand markets open in 6 hours 12 minutes

MRNA Jan 2024 230.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
30.22-1.11 (-3.54%)
As of 09:58AM EDT. Market open.
Full screen
Previous close31.33
Open30.22
Bid25.95
Ask29.90
Strike230.00
Expiry date2024-01-19
Day's range30.22 - 30.22
Contract rangeN/A
Volume1
Open interest380
  • Editor's pick
    Yahoo Finance Video

    UK approves COVID vaccine that targets Omicron subvariants

    Yahoo Finance reporter Anjalee Khemlani details how the U.K. has approved a vaccine that targets both the original and omicron variants of the coronavirus.

  • Motley Fool

    Why Moderna Stock Climbed Today

    Shares of Moderna (NASDAQ: MRNA) rose 3.3% on Monday after health regulators in the U.K. authorized the biopharmaceutical leader's bivalent COVID-19 vaccine booster for use in adults. Moderna's updated vaccine targets the original coronavirus strain and the currently fast-spreading omicron variants. On Monday, the Medicines and Healthcare products Regulatory Agency (MHRA) said the new bivalent booster meets its "standards of safety, quality, and effectiveness."

  • Motley Fool

    Is Moderna Stock a Buy Now After the U.K.'s Omicron Vaccine Approval?

    Shares of COVID-19 vaccine pioneer Moderna (NASDAQ: MRNA) moved higher on Monday morning, rising more than 3% as the company announced more good news with its virus-fighting efforts. Specifically, Moderna said that it has received approval for use in the U.K. for what the company is calling its "next-generation COVID-19 vaccine." The body oversees immunization approvals in the U.K., and this is the first time that it or any other regulatory agency has approved a bivalent vaccine designed to address the omicron variant.